All the news

Increases in liver enzymes are common in people with COVID-19 and occur more frequently in people with severe COVID-19, a meta-analysis of studies published in Hepatology International shows. Most liver enzyme elevations were ...

Sofosbuvir and daclatasvir, two antiviral drugs used to treat hepatitis C, were associated with faster recovery, shorter hospitalisation and improve survival among people with moderate or severe COVID-19, researchers reported this month at the ...

People with cirrhosis, especially those with diabetes or obesity, are more likely to suffer significant liver injury after contracting SARS-CoV-2 than others with chronic liver disease, Asian liver specialists report in a ...

High cure rates for hepatitis C can be achieved in Cameroon but the cost of treatment remains out of reach for all but the wealthiest, findings from a demonstration study of direct-acting antiviral ...

Diagnoses of infective endocarditis, a life-threatening bacterial infection of the heart valves, have become more common over the past ten years among people with hepatitis C and people with opioid use disorder ...

Non-alcoholic steatohepatitis (NASH), the severe form of non-alcoholic fatty liver disease (NAFLD), is now the most common reason for a liver transplant in women, older patients and people receiving Medicare insurance in the ...

The number of people with chronic hepatitis C infection in England has fallen by 30% since 2016 due to direct-acting antiviral treatment, says Public Health England in a new report on the ...

People with a genetic profile that strongly predicts non-alcoholic or metabolic-associated fatty liver disease were not at higher risk of being hospitalised with COVID-19 in the United Kingdom, an analysis of the ...

People with chronic liver disease admitted to hospital with COVID-19 are dying at a much higher rate than the rest of the population, figures collated by liver specialists in Europe, Asia and ...